losartan has been researched along with Cardiac Arrest, Sudden in 16 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 9.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
| "Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 9.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
| "The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment." | 5.17 | Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2013) |
| "The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
| " We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 5.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
| "The OPTIMAAL trial randomized 5477 patients with heart failure or evidence of left ventricular dysfunction following acute MI to losartan or captopril." | 5.11 | Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. ( Cleland, JG; Dickstein, K; Kjekshus, J; Orn, S; Romo, M, 2005) |
| "Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 5.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
| "Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okin, PM | 4 |
| Bang, CN | 1 |
| Wachtell, K | 3 |
| Hille, DA | 1 |
| Kjeldsen, SE | 3 |
| Dahlöf, B | 5 |
| Devereux, RB | 5 |
| Morin, DP | 1 |
| Oikarinen, L | 2 |
| Viitasalo, M | 2 |
| Toivonen, L | 2 |
| Nieminen, MS | 3 |
| John, M | 1 |
| Aronow, WS | 1 |
| Lindholm, LH | 2 |
| Edelman, JM | 1 |
| Ibsen, H | 2 |
| Borch-Johnsen, K | 1 |
| Olsen, MH | 2 |
| Snapinn, S | 1 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Lip, GY | 1 |
| Jern, S | 1 |
| Orn, S | 1 |
| Cleland, JG | 1 |
| Romo, M | 1 |
| Kjekshus, J | 1 |
| Dickstein, K | 1 |
| Krauser, DG | 1 |
| Fischer, R | 1 |
| Dechend, R | 1 |
| Gapelyuk, A | 1 |
| Shagdarsuren, E | 1 |
| Gruner, K | 1 |
| Gruner, A | 1 |
| Gratze, P | 1 |
| Qadri, F | 1 |
| Wellner, M | 1 |
| Fiebeler, A | 1 |
| Dietz, R | 1 |
| Luft, FC | 1 |
| Muller, DN | 1 |
| Schirdewan, A | 1 |
| Thygesen, K | 1 |
| Rump, LC | 1 |
| Oberhauser, V | 1 |
| Schwertfeger, E | 1 |
| Schollmeyer, P | 1 |
| Brooksby, P | 1 |
| Robinson, PJ | 1 |
| Segal, R | 1 |
| Klinger, G | 1 |
| Pitt, B | 1 |
| Cowley, AJ | 1 |
| Riegger, GA | 1 |
| Topol, E | 1 |
| Gavras, I | 1 |
| Gavras, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[ACE inhibitors or AT1 receptor antagonists?].
Topics: Age Factors; Aged; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In | 1999 |
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardi | 2000 |
7 trials available for losartan and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Confidence Intervals; Death, Sudden, C | 2013 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Elec | 2004 |
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Death, Sudden, Cardiac; Female; Follo | 2005 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiotonic Agent | 1999 |
ACE inhibitors still the drug of choice for heart failure--and more.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Death, Sudden, Cardiac | 1999 |
6 other studies available for losartan and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
Experimental evidence to support ELITE.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, | 1998 |